Category Archives: Jim’s Corner

BIO Principles Put Patients First

Greenwood_Jim_BTN

Patient advocacy organizations play an indispensable role in the biopharmaceutical development process: They help scientists and researchers better understand what it’s like to live with the diseases they’re trying to cure. That’s why BIO and our member companies are deeply committed to meaningful partnerships with patient advocacy organizations as we work to discover new medications to help patients live longer, healthier, more fulfilling lives. Today, there are more than 250 biotechnology health care medications and Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Despite Latest Report, ICER Still Limits Patient Input and Maintains Strong Ties To Insurers

Greenwood_Jim_BTN

After months of criticism, including some from BIO, the Institute for Clinical and Economic Review (ICER) released a document that tries to address many of the legitimate and persistent concerns that have been raised. We appreciate that ICER is taking such criticism more seriously, and recently opened up its methodology to more public comment.  However, after reviewing the document, it remains clear to us that ICER still doesn’t quite get why so many organizations, including Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,

The Washington Post Unfairly Attacks The Orphan Drug Act

Greenwood_Jim_BTN

The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled by Friday’s unfair article in The Washington Post targeting the Orphan Drug Act through selective and unsubstantiated attacks that seem designed to undermine this bipartisan and hugely successful regime that has helped so many patients with rare diseases live longer and healthier Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

New Avalere Study: Drugs Not Major Drivers Of Premium Growth, Dispels Insurance Industry Myth

new-bio-logo

Today, Avalere Health published a study that further dispels the pervasive myth that prescription drugs are a major driver of increased health insurance premiums. It is, in fact, outpatient spending and professional services that are the largest drivers of insurance premium growth—not prescription drugs, which represent only about 14 percent of premium growth.  Outpatient spending accounts for 29.9 percent of 2017 premium increase justifications. While professional services account for 27.7 percent. This data comes from Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , ,

Correcting the Record On Politico’s Misinformed Article

new-bio-logo

Politico recently explored the relationship between the biopharmaceutical industry and the Affordable Care Act (ACA). The article laments the supposed high cost of drugs and implicitly endorses policies that would not only do little for patients in need of medications, but also stifle innovation through research and development. The implication that the “structural reforms” the story talks about would fundamentally change drug costs in this country is myopic and misinformed. Those so-called “reforms” like top-down, Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , ,